Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD Pharmaceutical TechnologyOutlook's approval brings the first ophthalmic formulation of bevacizumab for the treatment of wet AMD.OphthalmologyRead full story pharminent July 27, 2026 (Last updated: July 28, 2026) Pharmaceutical Technology Outlook’s approval brings the first ophthalmic formulation of bevacizumab for the treatment of wet AMD. Ophthalmology Read full story Post navigation Previous: D.C. Circuit Affirms HHS Authority Over 340B Rebate ModelsNext: Outlook finally claims FDA approval for AMD drug Related Stories Regulatory Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval pharminent August 17, 2026 Regulatory UK regulators greenlight Lilly’s Foundayo, intensifying Novo competition pharminent August 11, 2026 Regulatory Replimune rebounds to win FDA approval of melanoma drug pharminent August 6, 2026
